GlobeNewswire by notified

Erasmus Medical Center, Rotterdam is partnering with Olink to deepen understanding of disease progression and accelerate the development of novel therapies

Share

UPPSALA, Sweden, June 16, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the Human Genomics Facility of the Erasmus Medical Center in Rotterdam has adopted the Olink technology, becoming the first Olink® Explore certified laboratory in the Netherlands.

The Rotterdam Human Genomics Facility (HuGe-F) houses one of Europe’s largest high-throughput genomics facilities, offering genomics services to global customers. This partnership offers a new opportunity to combine several layers of multi-omics approaches to unravel mechanisms of human disease biology and accelerate development of novel therapies.

“Together with the Proteomics Core Facility at Erasmus MC, we at HuGe-F now offer a full range of possibilities to measure proteins in all kinds of tissues. Within the field of population genomics, we see increasing interest in measuring large amounts of proteins in cohorts from around the world. The robust and sensitive Olink technology opens up novel opportunities to identify biological mechanisms underlying disease, especially when combined with other layers of genomic information such as genetic variation. “ said Joyce van Meurs, professor of Population Genomics, Head ofthe Human Genomics Facility of the Erasmus Medical Center, Rotterdam.

Olink® Explore will be utilized across a wide range of therapeutical areas to deepen current understanding of molecular pathways involved in the development, progression, and outcome of disease. The combination of genomics and large-scale proteomics will facilitate precision medicine efforts by completing the knowledge base of complex pathophysiological disease mechanisms, therapeutical targets, and biomarkers associated with drug targets.

“Within our department, we aim to unravel complicated immunological and metabolic pathways which play a role in chronic inflammation and infection. In one of our latest studies, the 2000HIV Human Functional Genomics Partnership Program, we include multiple layers of data to identify factors underlying immune dysregulation in people living with HIV,” said professor Leo Joosten,Internal Medicine department, Radboud UMC, Nijmegen. “Measuring proteomics using the Olink® Explore 3072 platform comprises an important part of this. Having a local opportunity to analyze our samples on the Olink® Explore 3072 platform is highly valuable. It allows us to identify circulating biomarkers and pathways related to common non-AIDS comorbidities such as cardiovascular disease and non-alcoholic fatty liver disease, as well as to the size and composition of the HIV reservoir.”

“This new partnership demonstrates further democratization of Olink technology and facilitates important work like that of professor Leo Joosten to run Olink® Explore3072 on his full HIV cohort. This is also very much in line with our mission to help the scientific community meet their goals to better understand the origin of disease, enable earlier and more accurate diagnoses and allow for more efficient and safer drug development. These efforts can fundamentally speed up the impact of high specificity proteomics on human health.” said Henk Mouthaan, Vice President Sales and Marketing EMEA, Olink Proteomics. 

Investor Contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
mailto:andrea.prander@olink.com

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

Aboutthe Human Genomic Facility (HuGe-F)
The Laboratory of Population Genomics of the Department of Internal Medicine at Erasmus MC, the largest academic hospital in the Netherlands, houses one of Europe’s largest high-throughput genomics facilities.It has been active for 20 years, handled millions of samples, and is enabling application of the most advanced genomic technologies to research projects of customers, both in- and outside The Netherlands. In addition, HuGe-F offers help regarding study design and data analysis including data storage. HuGe-F is closely connected to the Laboratory of Population Genomics, which focusses on research in the field of genetics and genomics of complex traits and common diseases. HuGe-F is a certified laboratory and works for academic, commercial, and clinical customers.

Forward-Looking Statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Arcoma vinner viktig upphandling i Finland. (MAR)27.6.2022 13:00:00 CEST | Pressemelding

2022-06-27 PRESSRELEASE Arcoma vinner viktig upphandling i Finland. Arcoma AB har vunnit viktig upphandlingpå upp till 6Arcoma Precision i5-system till ”HUS Medical Imaging Center” i Finland.Tre av systemen kommer att installeras under 2022 och kontraktet har en option på ytterligare tre system för installation under 2023. Det totala ordervärdet är upp till cirka 7,5MSek, beroende på tillval och optioner. Upphandlingen är vunnen av Lifemed Medical Systems som är Arcomas distributör och samarbetspartner i Finland och slutkunden är ”HUS Medical Imaging Center” som är en del av Helsingfors universitetssjukhus. "Vi är mycket glada över denna möjlighet att leverera dessa system till HUS, tillsammans med vår partner Arcoma. Ergonomi, patientsäkerhet och bra bildkvalitet var nyckelfaktorerna i detta anbud och Precision i5 är en perfekt lösning för att möta dessa behov ”, säger Mikko Isoviita, Sales Manager Lifemed Medical Systems. "Det är mycket glädjande att vi genom Lifemed vunnit denna upp

Arcoma wins important procurement in Finland. (MAR)27.6.2022 13:00:00 CEST | Press release

2022-06-27 PRESSRELEASE Arcoma wins important procurement in Finland. Arcoma AB has won important procurement of up to 6 Arcoma Precision i5 systems to “HUS Medical Imaging Center” in Finland. Three of the systems will be installed in 2022 and the contract has an option for three more systems for installation in 2023. The total order value is up to approximately SEK 7.5 million, depending on options. The procurement was won by Lifemed Medical Systems, which is Arcoma's distributor and partner in Finland, and the end customer is the “HUS Medical Imaging Center”, which is part of Helsinki University Hospital. "We are very pleased for this opportunity to supply these systems to HUS, together with our long-term partner Arcoma. Ergonomics, patient safety and good image quality were they key factors in this tender and Precision i5 is a perfect solution to address these needs”, says Mikko Isoviita, Sales Manager Lifemed Medical Systems. "It is great that we through Lifemed have won this procu

Change in Aspo’s Group Executive Committee27.6.2022 10:20:00 CEST | Press release

Aspo Plc Stock exchange release June 27, 2022 at 11:20 a.m. Change in Aspo’s Group Executive Committee Heli Arantola, Managing Director of Aspo’s subsidiary Leipurin, has resigned to join another company. Arantola will leave the company in December at the latest, and the process of selecting her successor has begun. “I thank Heli for her excellent contribution to the modernization of Leipurin and transforming the company in the rapidly changing bakery and food industry. I wish her the best of luck in her future endeavors,” says Rolf Jansson, CEO of Aspo Group. Aspo Plc Rolf Jansson CEO Further information, please contact: Rolf Jansson, CEO, Aspo Plc, +358 400 600 264, rolf.jansson@aspo.com DISTRIBUTION: Nasdaq Helsinki Key media www.aspo.com Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of

Cool Company Ltd. – Mandatory Notification Of Trade27.6.2022 10:17:48 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 24 June 2022 acquired 7,035 shares in the Company at a price of NOK 89.307527 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,598,523 shares in the Company, equivalent to 38.99% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme27.6.2022 08:45:00 CEST | Press release

Company Announcement No. 43/2022 Copenhagen, 27 June 2022 Transactions in connection with share buy-back programme On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023. The